Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke
Luke R. Lemmerman, Maria Balch, Jordan Moore, Diego Alzate‐Correa, María A. Rincon‐Benavides, Ana I. Salazar‐Puerta, Surya Gnyawali, Hallie Harris, William Lawrence, Lilibeth Ortega‐Pineda, Lauren Wilch, Ian B. Risser, Aidan J. Maxwell, Silvia Duarte‐Sanmiguel, Daniel Dodd, Gina P. Guio-Vega, Dana M. McTigue, W. David Arnold, Shahid M. Nimjee, Chandan K. Sen, Savita Khanna, Cameron Rink, Natalia Higuita‐Castro, Daniel Gallego‐Perez
Abstract
-nanotransfected fibroblasts. Together, our results suggest that vasculogenic cell therapies based on nanotransfection-driven (i.e., nonviral) cellular reprogramming represent a promising strategy for the treatment of ischemic stroke.
Topics & Concepts
ReprogrammingIschemic strokeStroke (engine)MedicineCancer researchCellNeuroscienceCardiologyIschemiaBiologyPhysicsGeneticsThermodynamicsMesenchymal stem cell researchNeuroinflammation and Neurodegeneration MechanismsExtracellular vesicles in disease